European regulator leans on Illumina to break off Grail, its $8 billion early cancer detection company


Illumina took a $3.9 billion goodwill charge in the third quarter for Grail.

Previous East Bay startup Infinimmune's secret for building better antibody drugs: You
Next 3 Denver-area hospitals rank among the best for maternity care